Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30771989 | 1.00 | SSTR4 (0.41) | SSTR4MAPTPKMRENADRB2 | |
| Hydrochloric Acid SCHEMBL19118556 | 0.98 | MAPT (0.42) | SSTR4MAPTPKMRENADRB2 | |
| Trifluoroacetic Acid SCHEMBL3011885 | 0.90 | SSTR4 (0.39) | SSTR4MAPTPKMRENPPM1B | |
| SCHEMBL16327862 | 0.87 | SSTR4 (0.38) | SSTR4MAPTPKM | |
| SCHEMBL533645 | 0.84 | SSTR4 (0.38) | SSTR4REN | |
| SCHEMBL7288516 | 0.83 | NAAA (0.38) | SSTR4REN | |
| SCHEMBL10811808 | 0.82 | SSTR4 (0.34) | SSTR4MAPTPKMRENSLC6A2 | |
| SCHEMBL27492135 | 0.82 | ALDH1A1 (0.38) | MAPTPKMPPM1BPTPN1PPP1CC | |
| SCHEMBL2910492 | 0.80 | SSTR4 (0.48) | SSTR4REN | |
| SCHEMBL22873631 | 0.80 | SSTR4 (0.48) | SSTR4REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382270-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250340514-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| US-12398103-B2 | 3-diarylmethylenes and uses thereof | ATUX ISKAY LLC (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4554944-A2 | KINASE INHIBITORS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12084426-B2 | Indazole carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-10 | — | — | US | disclosed |
| CN-112673001-B | Indazole carboxamides as kinase inhibitors | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024020333-A2 | KINASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024001839-A1 | HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
| US-5206343-A | Oligopetides with cyclic proline-analogous amino acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| EP-0226267-B1 | OXA-, THIA- AND DIAZABICYCLOALKANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BEECHAM GROUP PLC (GB) | 1993-01-13 | — | — | EP | disclosed |
| EP-0401929-A2 | Method of preparing N-oxotetrahydro- -carbolines | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-12-12 | — | — | EP | disclosed |
| US-4883874-A | Azabicyclic intermediates | BEECHAM GROUP PLC. OF BEECHAM HOUSE (GB) | 1989-11-28 | — | — | US | disclosed |
| US-4826839-A | GASTROINTESTINAL DISORDERS, HEADACHES | BEECHAM GROUP P.L.C. (GB) | 1989-05-02 | — | — | US | disclosed |
| US-4681938-A | Novel polycyclic hydrazones of rifamycins, their manufacture, and their pharmaceutical compositions for treating tuberculosis | CIBA-GEIGY CORPORATION (US) | 1987-07-21 | — | — | US | disclosed |
| EP-0226267-A1 | Oxa-, thia- and diazabicycloalkane derivatives, process for their preparation and their use as pharmaceuticals | BEECHAM GROUP PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| US-4551450-A | ANTITUBERCULOTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382270-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | SSTR4 4050/4885MAPT 2576/4885PKM 1631/4885 |
| US-12398103-B2 | 3-diarylmethylenes and uses thereof | MYC, MYCBP, FOXO1 | SSTR4 4050/4885MAPT 2576/4885PKM 1631/4885 |
| US-20250340514-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | SSTR4 4050/4885MAPT 2576/4885PKM 1631/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | SSTR4 3508/4885MAPT 2953/4885PKM 469/4885 |
| US-12084426-B2 | Indazole carboxamides as kinase inhibitors | RIPK3, RIPK1, RIPK2 | SSTR4 4302/4885MAPT 2768/4885PKM 738/4885 |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | TFAM, CS, FH | SSTR4 4302/4885MAPT 1016/4885PKM 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.